Elliott M. Antman
Brigham and Women's Hospital
765 Papers
17.4K Citations
Elliott M. Antman is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & Medicine. The author has an hindex of 161, co-authored 716 publications. Previous affiliations of Elliott M. Antman include Duke University & Katholieke Universiteit Leuven.
Chat about Author
Papers
Serum Levels of the Interleukin-1 Receptor Family Member ST2 Predict Mortality and Clinical Outcome in Acute Myocardial Infarction
Masahisa Shimpo,David A. Morrow,Ellen O. Weinberg,Marc S. Sabatine,Sabina A. Murphy,Elliott M. Antman,Richard T. Lee +6 more
TL;DR: Serum levels of the interleukin-1 receptor family member ST2 predict mortality and heart failure in patients with acute myocardial infarction, suggesting that ST2 may be a useful biomarker and that this novel inflammatory receptor may play a role in cardiac pathophysiology.
ACCF/ACG/AHA 2010 expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: A focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use
Neena S. Abraham,Mark A. Hlatky,Elliott M. Antman,Deepak L. Bhatt,David J. Bjorkman,Craig Clark,Curt D. Furberg,David A. Johnson,Charles J. Kahi,Loren Laine,Kenneth W. Mahaffey,Eamonn Martin Quigley,James M. Scheiman,Laurence S. Sperling,Gordon F. Tomaselli +14 more
TL;DR: The ACCCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines focused on reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use.
Efficacy of propafenone in Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up.
TL;DR: Propafenone is a very promising agent for emergency intravenous therapy as well as long-term oral therapy in patients with Wolff-Parkinson-White syndrome and during electrophysiologic study, it caused a marked decrease in peak ventricular rate during atrial fibrillation.
Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction).
James Aisenberg,Prapti Chatterjee-Murphy,Kathryn Friedman Flack,Jeffrey I. Weitz,Christian T. Ruff,Francesco Nordio,Michele Mercuri,Youngsook Choi,Elliott M. Antman,Eugene Braunwald,Robert P. Giugliano +10 more
TL;DR: The correlation between dose, trough edoxaban level, and the risk of GIB risk suggests GIB is exposure-related, whereas surgery required to manage bleeding was less frequent with HD-ER and warfarin.
Risk of Initiating Antiarrhythmic Drug Therapy for Atrial Fibrillation in Patients Admitted to a University Hospital
William H. Maisel,Karen M. Kuntz,Sharon C. Reimold,Thomas H. Lee,Elliott M. Antman,Peter L. Friedman,William G. Stevenson +6 more
TL;DR: The purpose of this study was to determine the incidence, time course, and predictors of early adverse cardiac events in a large series of patients undergoing in-hospital observation during the initiation of antiarrhythmic therapy for atrial fibrillation.